The incidence of malignant tumors in renal allograft recipients is higher than in the general population. Kidney carcinomas represent 4.8% of the tumors in transplant patients. Only 10% of them occur in the transplanted kidney. Graft tumors can be transmitted by donors, metastases from the recipient's native organs, or de novo development after transplantation. The mean time to diagnosis of the tumor after transplantation is 10 years. We report the case of a 45-year old male patient with an incidental locally confined 15 mm renal cell carcinoma detected in allograft kidney's lower pole 16 years after the transplantation. The patient successfully underwent a minimally invasive procedure -percutaneous radiofrequency ablation, completely eliminating the tumor and preserving graft function with no signs of early complications. One year after the procedure, there is no evidence of oncological disease recurrence or late complications and the patient maintains an adequate graft function with no need for hemodialysis.
Introduction
Kidney transplantation still remains the best treatment choice for patients with end-stage renal disease taking into account the survival and quality of life. However, it is estimated, that in about 6% of transplant recipients some kind of neoplasm will develop, mostly skin malignancies and non-Hodgkin lymphomas [1, 2] . Kidney carcinomas represent 4.8% of post-transplant cancers, as compared with 2.3% of tumors in the general population. However, among these carcinomas, only 10% occur in kidney grafts [3, 4] . Graft tumors can be transmitted by donors, metastases from the recipient's native organs, or de novo development after transplantation [5] . An increase in the detection of mostly incidental tumors in renal transplants is associated with the increasing use of transplants from elderly donors and long-term immunosuppression [6] . Moreover, monitoring alone (regular ultrasound screening) can enhance the number of incidental tumors detected [6, 7] . The mean time to diagnosis of the tumor after transplantation is 10 years, although, in our case, it took 16 years [7] . Radical and nephron-sparing nephrectomies have been the treatments of choice for transplant patients for a long time but percutaneous ablative therapy, which is minimally invasive procedure with lower morbidity, is now considered as a well-established therapeutic approach and taking its place in treatment algorithms [8] . Due to the rarity of allograft kidney tumors and very few articles involving treatment with percutaneous thermal ablation, our aim is to share our experience and short-term results.
Clinical case presentation
We present the case of a 45-year old male patient with medical history of arterial hypertension, gastric ulcers and an end-stage renal disease caused by chronic glomerulonephritis. In 1998, the patient received a kidney transplant from a live donor (his brother) in the right iliac fossa. Maintenance immunosuppressive therapy included Methylprednisolone, Azathioprine and Cyclosporine. In 2009, a routine ultrasound showed 1st grade hydronephrosis, which progressed. A computer tomography (CT) scan was carried out but no clear cause of hydronephrosis or any lesions were identified at that time. The kidney graft function was limited: glomerular filtration rate 30 (ml/min/1.73 m 2 ), and creatinine levels stable in an 18-month period (221→198→264→222 µmol/l). In September 2014, a CT scan (without contrast since the serum creatinine level was high) detected a pyeloureteral stricture and a solid ~15 mm lesion in the transplant kidney's lower pole parenchyma. It should be noted that the lesion had no influence to the nephrostasis and was incidental. By revising the prior CT scans made in 2009, a smaller lesion in the same location that had not been reported earlier was detected. The tumor was slowly growing from <10 mm to ~15 mm in a 5 years' period. After the needle biopsy, primary results showed xanthogranulomatous pyelonephritis and nephrosclerosis. It was decided to perform pyeloplasty and ureter stenting to eliminate the cause of hydronephrosis (pyeloureteral stricture) and preserve the graft kidney function. The further treatment tactics were planned to be discussed after the final histology results. The final biopsy results confirmed the disease corresponded to papillary carcinoma (G3, grade 3 Fuhrman). Taking into consideration eligible tumor size (TNM T1a), location, graft function and available equipment, a minimally invasive procedure would have been the best choice of treatment. Thus it was proposed to carry out percutaneous radiofrequency ablation therapy (RFA). RFA with intraoperative ultrasound targeting was performed in October 2014. Graft's lower pole ~13 mm solid tumor was destructed using two T20 (15 cm) needles, 40W power, 30 KJ energy (in 66 minutes). Prophylactic antibiotics were prescribed before and after the procedure. The patient was released from the hospital 3 days after the operation with no complications and adequate renal function. CT scan control after 2, 6 and 12 months detected no evidence of disease recurrence or late complications. The patient maintained an adequate allograft function with no need for hemodialysis.
Discussion
Transplant patients must stay on immunosuppressive therapy, therefore, they gain a higher risk of developing some kind of neoplasm. The risk of renal cell carcinoma (RCC) is two times bigger in transplant patients than in general population [3] . The incidence of de novo carcinoma in kidney allografts is reported to be 0.19-0.5% [8, 9] . Graft tumors can be transmitted by donors, metastases from the recipient's native organs, or de novo development after transplantation [5]. Penn considered kidney graft tumors detected within 2 years after the transplantation to be most likely transmitted [4] . However, the reported time between the transplantation and the development of de novo RCC in transplanted kidneys is ranging from 9 months to 27 years [7, 11] . Based on Tillou et al. exhaustive literature review, the mean time to diagnosis of the tumor after transplantation is 126.2 ± 69.8 months [7] . The estimated growth of these tumors is between 5 and 10 mm per year, thus identical to the tumors found in native kidneys and in patients without transplants [12] . In our case, the tumor is diagnosed 16 years after the transplantation, although, a small lesion was detected revising CT scans made in 2009. Comparing CT scans done in 2009 and 2014, the tumor size enlarged only ~1 cm in 5 years.
The diagnosis of a graft kidney malignancy is typically incidental, usually during the regular follow-up imaging. The diagnosis is made using abdominal ultrasound or a CT scan. Similar to native kidney tumors, symptomatic kidney graft tumors have a worse prognosis [13] .
Cornelis et al. found that renal papillary carcinoma accounted for 85% of the histologic subtypes found in transplant patients, compared with the 10%-15% of these subtypes encountered in the general population [6, 12] . According to Gelb, this type of tumor has a better prognosis in comparison to clear cell carcinoma [14] . Papillary carcinoma represented 55.7% of the tumors in the Tillou et al. study (2012) [9] , although the later systematic review revealed the most common tumor was clear cell carcinoma (46.4% versus 43.7%). Study found an overall 79.1% of low-grade tumors (Grade 1 and 2 of Fuhrman), therefore concluded that de novo graft tumors seemed to be predominantly low-grade and not aggressive [7] . In our case the tumor was a high-grade (G3, grade 3 Fuhrman) confined (TNM T1a) papillary carcinoma.
Renal transplant recipients with graft RCC present a dilemma: if a conservative approach was chosen to preserve the graft, the patient would be placed at a greater risk of cancer progression due to immunosuppressant induced immune incompetence. Therefore, such tumors are approached surgically at the risk of losing the only functioning kidney. Transplantectomy is usually justified by symptomatic and >40 mm graft tumors (TNM T2 or higher) [7, 15] . Nephron sparing surgery (NSS) is recommended for graft kidney tumors ≤40 mm (TNM T1b) with an eccentric location and a good blood supply to the rest of the allograft parenchyma [9, 10, 16] . However, NSS is now recommended by the European Association of Urology guidelines for native kidney tumors >40 mm (TNM T1b) [7, 15] . NSS preserves graft functions and helps patients to avoid returning to dialysis that is associated with inferior life expectancy and quality of life. Nevertheless, NSS can appear technically difcult because it is performed in a non-naive surgical field making kidney mobilization, parenchymal resection and other manipulations complex [17] .
The growth of interest in minimally invasive procedures has been triggered by finding the relation between the number of functional nephrons left after the tumor resection and patient survival [18] . Two minimally invasive techniques used in <40 mm (TNM T1a) RCC treatment are RFA and cryoablation. RFA is perfectly suited in such cases as it only slightly reduces the number of nephrons (RFA 11% versus NSS 35%) and does not require intraoperative ischemia that might induce associated parenchymal injury [19] . Based on Regier and Chun systematic review, the primary technical success rate of RFA in non-transplant patients ranged from 88% to 100% with the complication rate from 1% to 7%. [20] . Cornelis et al. had 100% success rate with one complication in their 24 graft RCC patient group, which resembled to other studies [6] . Therefore, it can be assumed that the results in transplant and non-transplant patients are similar. The few authors who reported their primary success rates after cryoablation found them somewhat higher compared to RFA. Moreover, the result of the ablation can be instantly visualised with ultrasound control during the intervention as a hypodense ice ball. However, there are no randomized controlled trials comparing the two techniques [20] . In the present case, the tumor in a graft kidney with limited function was successfully treated with RFA with no cancer progression after 12 months as verified by CT.
Conclusions
Percutaneous radiofrequency ablation therapy is a feasible option for patients with small (TNM T1a) kidney graft tumors or in such cases, when the patient is not eligible for surgery (surgery refusal, old age or other treated cancers). Due to minimal invasiveness, high success rate, low complication rate, low mortality and short hospital stay, percutaneous radiofrequency ablation technique is an important addition to the selection of effective treatments for locally confined renal tumors, especially in functioning allografts.
